News coverage about Sucampo Pharmaceuticals (NASDAQ:SCMP) has trended somewhat positive on Monday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.8302559752764 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of research analysts have recently commented on the company. UBS Group lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price target for the company. in a report on Friday, January 5th. B. Riley lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 target price for the company. in a research note on Tuesday, December 26th. BidaskClub lowered Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 14th. ValuEngine upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research lowered Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $20.25.
Sucampo Pharmaceuticals (SCMP) opened at $18.00 on Monday. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. The company has a market capitalization of $839.46, a price-to-earnings ratio of -5.37, a P/E/G ratio of 5.06 and a beta of 1.38. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $18.75.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.